Selegiline-d5

Selegiline-d5 (Deprenyl-d5) is deuterium labeled Selegiline. Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC50 of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC50=23 μM) . Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder[1][2][3].

Product Specifications

CAS Number

[1217976-51-6]

Product Name Alternative

Deprenyl-d5; (-) -Selegiline-d5; (-) -Deprenyl-d5

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Monoamine Oxidase

Related Pathways

Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

C#CCN(C)[C@H](C)CC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H]

Molecular Formula

C13H12D5N

Molecular Weight

192.31

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Chaurasiya ND, et, al. Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana) . Molecules. 2019 Feb 23;24 (4) :810.|[3]Tatton WG, et, al. Modulation of gene expression rather than monoamine oxidase inhibition: (-) -deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996 Dec;47 (6 Suppl 3) :S171-83.|[4]MohanKumar PS, et, al. Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro. Brain Res Bull. 2001 Apr;54 (6) :675-80.|[5]Ho MC, et, al. Chronic treatment with monoamine oxidase-B inhibitors decreases cocaine reward in mice. Psychopharmacology (Berl) . 2009 Jul;205 (1) :141-9.